ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen: 84% Of Micromet Shares Have Been Tendered

DOW JONES NEWSWIRES Amgen Inc. (AMGN) said nearly 84% of the shares of biotechnology company Micromet Inc. (MITI) have been tendered to its $1.16 billion takeover offer, meeting all the conditions for the acquisition to close. As of the offering's expiration Thursday, about 80 million Micromet shares had been tendered and not withdrawn. An added 3.15 million shares have been tendered by guaranteed delivery. A subsequent offering period is scheduled to expire at 12:00 a.m. EST, at the end of March 6. Amgen launched its bid to acquire Micromet in January with an aim to strengthen Amgen's cancer-drug research pipeline. A Delaware judge declined to block Amgen's purchase of Micromet, the Associated Press reported Thursday. A group of Micromet shareholders had argued that Micromet didn't try hard enough to get a better offer, and sought a preliminary injunction. The judge found that the shareholders didn't show a reasonable likelihood that they would successfully prove their claims, the AP reported. Amgen shares closed at $67.59 Thursday and were inactive premarket. The stock is up 32% in the past 12 months. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
02/14/201718:12:25Automatic Shelf Registration Statement of Securities of Well-known...
02/14/201717:07:24Annual Report (10-k)
02/14/201710:47:10Statement of Ownership (sc 13g)
02/14/201709:00:00Amgen Submits Supplemental Biologics License Application For...
02/13/201716:41:37Amended Statement of Ownership (sc 13g/a)
02/09/201712:01:10Amended Statement of Ownership (sc 13g/a)
02/08/201719:32:00Appeals Court Allows Sanofi, Regeneron to Continue Selling Cholesterol...
02/07/201718:13:00FDA Approves Amgen's Parsabiv™ (Etelcalcetide), First New Treatment I...
02/03/201717:08:12Current Report Filing (8-k)
02/03/201716:04:00Amgen Announces Appointment of Charles M. Holley Jr. to Board...
02/03/201712:59:00Good News for Amgen Is God News for Biotech
02/02/201719:20:00Correction to Amgen Repatha Story
02/02/201718:54:30Statement of Changes in Beneficial Ownership (4)
02/02/201718:48:51Statement of Changes in Beneficial Ownership (4)
02/02/201717:07:00Amgen Sees Positive Results in Repatha Study -- 2nd Update
02/02/201717:02:00Amgen Sees Positive Results in Repatha Study
02/02/201716:56:39Current Report Filing (8-k)
02/02/201716:36:00Amgen's Profit Rises on Improved Margins, Steady Top-line Growth
02/02/201716:20:00Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
02/02/201716:00:00Amgen Announces Repatha® (Evolocumab) Significantly Reduced...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US